Association of circulating levels of apolipoprotein M and adiponectin with insulin sensitivity in overweight subjects and obese patients with weight loss surgery

Background: Most adipokines are up-regulated with obesity and promote metabolic dysfunction, while few, like adiponectin, are down-regulated during adipose tissue expansion and probably protect against obesity-related disorders. High adiponectin is linked to low inflammation and insulin sensitivity. Similarly, apolipoprotein M (apoM) was recently identified as an adipokine for which the expression in adipose tissue is positively associated with metabolic health. Our aim was to compare circulating levels of apoM to those of adiponectin in overweight and obese individuals with respect to metabolic parameters and insulin sensitivity. Methods: Adiponectin and apoM and were measured in a cross-sectional study including 169 overweight men and in a surgery-induced weight loss program including 13 obese patients of both sexes who underwent sleeve gastrectomy. Correlations between the homeostasis model assessment of insulin resistance (HOMA-IR) index, bioclinical parameters, adiponectin and apoM levels, and lifestyle habits were assessed using Spearman correlation coefficients. Multiple regression analyses of HOMA-IR were performed. Results: In overweight men, plasma adiponectin and apoM were lower in participants with diabetes. The apoM level did not correlate with that of adiponectin and was higher in individuals with dyslipidemia. Similar to adiponectin, apoM was negatively associated with HOMA-IR (r = -0.29), hs-CRP (r = -0.28) and HDL markers (HDL-C, r = 0.32; apoA-I, r = 0.32). Unlike adiponectin, apoM did not correlate with triglyceride levels but was positively associated with LDL markers (LDL-C, r = 0.27; apoB100, r = 0.20) and negatively with fat mass (r = -0.26) and age (r = -0.25). In multiple regression models, apoM was the only negative determinant of HOMA-IR, while adiponectin did not contribute to HOMA-IR variability. Accordingly, while sleeve gastrectomy improved insulin sensitivity, change in HOMA-IR at one year of follow-up was strongly negatively associated with change in the level of circulating apoM (r = -0.71) but not with change in the adiponectin level. Conclusions: Both circulating apoM and adiponectin are negatively correlated with bioclinical variables associated with obesity, inflammation, and insulin resistance. Unexpectedly, apoM, but not adiponectin, was a negative determinant of HOMA-IR. We identified for the first time circulating apoM as a novel biomarker of insulin sensitivity.

[1]  M. Krempf,et al.  Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study , 2021, Metabolites.

[2]  S. Shikora,et al.  Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters , 2021, Obesity Surgery.

[3]  G. Shulman,et al.  Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice , 2020, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Ruidavets,et al.  A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: comparison with conventional ELISA , 2020, medRxiv.

[5]  Dan Liu,et al.  Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility , 2020, Scientific Reports.

[6]  D. Rader,et al.  Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure , 2020, Circulation.

[7]  N. Viguerie,et al.  Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome. , 2019, Current opinion in lipidology.

[8]  T. Funahashi,et al.  Adiponectin, a unique adipocyte-derived factor beyond hormones. , 2019, Atherosclerosis.

[9]  J. Heeren,et al.  The endocrine function of adipose tissues in health and cardiometabolic disease , 2019, Nature Reviews Endocrinology.

[10]  A. Valsesia,et al.  Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. , 2019, The American journal of clinical nutrition.

[11]  C. Christoffersen,et al.  Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology , 2019, Current opinion in lipidology.

[12]  P. Formisano,et al.  Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications , 2019, International journal of molecular sciences.

[13]  Liu Yang,et al.  Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[14]  S. Swendeman,et al.  An engineered S1P chaperone attenuates hypertension and ischemic injury , 2017, Science Signaling.

[15]  Yajing Wang,et al.  Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification , 2017, Trends in Endocrinology & Metabolism.

[16]  Puhong Zhang,et al.  Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case–control study , 2016, Lipids in Health and Disease.

[17]  P. Scherer,et al.  Adiponectin, the past two decades. , 2016, Journal of molecular cell biology.

[18]  M. Fasshauer,et al.  Adipokines in health and disease. , 2015, Trends in pharmacological sciences.

[19]  C. Christoffersen,et al.  Apolipoprotein M in lipid metabolism and cardiometabolic diseases , 2015, Current opinion in lipidology.

[20]  J. Ruidavets,et al.  Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study[S] , 2013, Journal of Lipid Research.

[21]  Richard N Bergman,et al.  Gastrointestinal hormones and bariatric surgery‐induced weight loss , 2013, Obesity.

[22]  H. Buchwald,et al.  Metabolic/Bariatric Surgery Worldwide 2011 , 2013, Obesity Surgery.

[23]  J. Ruidavets,et al.  Adiponectin and Long-Term Mortality in Coronary Artery Disease Participants and Controls , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Rennian Wang,et al.  Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes , 2012, Nature Medicine.

[25]  M. Whooley,et al.  Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. , 2012, Atherosclerosis.

[26]  B. Dahlbäck,et al.  Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. , 2011, Atherosclerosis.

[27]  B. Wolffenbuttel,et al.  Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. , 2010, Atherosclerosis.

[28]  G. Watts,et al.  Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. , 2010, Atherosclerosis.

[29]  B. Dahlbäck,et al.  Apolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects , 2009, Journal of internal medicine.

[30]  B. Dahlbäck,et al.  Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[31]  B. Dahlbäck,et al.  Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? , 2009, Cellular and Molecular Life Sciences.

[32]  N. Abdella,et al.  Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes , 2007, International Journal of Obesity.

[33]  Shinji Kihara,et al.  Adiponectin: a key adipocytokine in metabolic syndrome. , 2006, Clinical science.

[34]  David Couper,et al.  Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2004, Diabetes.

[35]  R. Vigneri,et al.  Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  T. Ogihara,et al.  Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[37]  K. Clément,et al.  Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. , 2002, Human molecular genetics.